Prevalence and associated factors of treatment failure among children on ART in Ethiopia: A systematic review and meta-analysis.

BACKGROUND: As the use of antiretroviral therapy (ART) increases, the issue of treatment failure is still a global challenge, particularly in a resource limited settings including Ethiopia. The results of former studies in Ethiopia were highly variable and inconsistent across studies. Thus, this systematic review and meta-analysis intended to provide the pooled estimation of treatment failure and associated factors among children on antiretroviral therapy.
METHODS: We searched international databases (i.e., PubMed, Google Scholar, Web of Science, Ethiopian Universities' online repository library, Scopus, and the Cochrane Library) during the period of February 30 to April 7, 2021. All identified observational studies reporting the proportion of treatment failure among HIV positive children in Ethiopia were included. Heterogeneity of the studies was checked using I2 test and Cochrane Q test statistics. We run Begg's regression test to assess publication bias. A random-effects meta-analysis model was performed to estimate the pooled prevalence of treatment failure.
RESULTS: The estimated pooled prevalence of treatment failure among children in Ethiopia was 12.34 (95%CI: 8.59, 16.10). Subgroup analysis of this review showed that the highest prevalence was observed in Addis Ababa (15.92%), followed by Oromia region (14.47%). Poor ART adherence (AOR = 2.53, CI: 2.03, 4.97), advanced WHO clinical staging (AOR = 1.66, CI: 1.24, 3.21), and opportunistic infections (AOR = 2.64 CI: 2.19, 4.31 were found to be significantly associated factors with childhood treatment failure.
CONCLUSIONS: This study revealed that treatment failure among children on ART was high in Ethiopia. Poor ART adherence, advanced WHO clinical staging, opportunistic infections, and low level of CD4 cell counts increased the risk of treatment failure.

Introduction

Acquired immune deficiency syndrome (AIDS) is a viral disease caused by human immunodeficiency virus (HIV) that weakens the immune system and makes the body susceptible to opportunistic infections [1]. The Human Immunodeficiency Virus (HIV) pandemic affects many parts of the world population [2]. In 2018, approximately 37.9 million people were living with HIV worldwide. Of which, around 1.8 million were children (age <15 years) [3]. In Ethiopia, 56,514 children were living with HIV in 2018 [4]. In this year, 23.3 million HIV-positive people were gain access to antiretroviral therapy (ART) globally [5].

Antiretroviral therapy (ART) is crucial to decrease progress of HIV/AIDS by suppressing viral replication which in turn reestablishes the immune function of HIV-infected individuals [6,7]. In addition, ART can minimize the risk of HIV transmission [8,9]. However, maintaining long-term adherence level, and viral load suppression, and prevention of treatment failure (TF) remains a serious challenge for HIV-infected children [10]. Even if ART is not curative medicine, it reduces the risk of HIV associated morbidity and mortality [11]. Treatment failure can be assessed based on World Health Organization (WHO) criteria, as immunological, clinical, virological, or combination of those failure [12].

The current guidelines recommend that, virological failure is more informative to assess treatment failure [13]. The Joint United Nations Program on HIV/AIDS (UNAIDS) and partners launched, 90% of individuals on ART would be virally suppressed at the end of 2030 worldwide [12,14]. Therefore, implementing globally recommended preventive measures and early detection of treatment failure is vital for treatment effectiveness and for achieving a stated strategic treatment plan of 2030 [15,16]. Likewise, the Ethiopian government also implemented various preventive strategies, such as timely initiation of ART, increasing knowledge and attitudes of patients towards ART, carrying out food and nutrition policy, prevention and control of opportunistic infections, and improving level of ART adherence [17].

In Ethiopia, studies were conducted to estimate the magnitude as well as to identify associated factors of treatment failure among HIV-infected children [18-27]. These small and fragmented studies demonstrated that TF among children on ART fluctuated from 3.1% in southern Ethiopia [21] to 22.6% in Addis Ababa [27]. However, the existed discrepancy and variabilities have not yet been investigated.

Additionally, there was no a country wide data which represents a national treatment failure and its associated factors among HIV positive children. Hence, the aim of this systematic review and meta-analysis was to estimate the pooled prevalence and associated factors of treatment failure among children on ART using available studies in Ethiopia. The findings of this systematic review and meta-analysis will highlight the prevalence and associated factors of TF with implications to improve health care workers’ interventions, assist decision makers and other concerned stakeholders to design, implement and evaluate interventions to improve level of ART adherence. Furthermore, the findings will enable the country to sustain treatment successes and to hasten the decline of childhood treatment failure in Ethiopia.

Materials and methods

Reporting

The result of this systematic review and meta-analyses was prepared and reported using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline [28]. The protocol has been registered in the PROSPERO database with a registration number of CRD-248210.

Study design, settings and search strategies

We carried out a systematic review and meta-analysis to estimate the pooled prevalence of TF and associated factors among HIV-positive children in Ethiopia which is located in east Africa. To find potentially relevant articles, a comprehensive search was carried out on PubMed, Web of Science, Google Scholar, Scopus, and Cochrane Library databases. To find unpublished relevant literatures to this study, some online repository library centers were searched. Besides, gray literatures were searched from review of reference lists and input of content experts. MeSH (Medical Subject Headings), Boolean operators and all fields within records were used to search in the advanced PubMed search engine. Search terms or phrases used were: children, child, pediatrics, treatment failure, antiretroviral therapy, prevalence, and associated factors.

The advanced PubMed database search strategy was performed using the following key terms (((((((Children(tw) OR child(tw) OR pediatrics(tw))) OR (("child"[MeSH Terms] OR "child"[All Fields] OR "children"[All Fields]) AND tw[All Fields] OR ("child"[MeSH Terms] OR "child"[All Fields]) AND tw[All Fields] OR ("paediatrics"[All Fields] OR "pediatrics"[MeSH Terms] OR "pediatrics"[All Fields]) AND tw[All Fields]))) AND (((Treatment failure(tw) OR immunological failure(tw) OR clinical failure(tw) OR virological failure(tw))) OR (("treatment failure"[MeSH Terms] OR ("treatment"[All Fields] AND "failure"[All Fields]) OR "treatment failure"[All Fields]) AND tw[All Fields] OR (immunological[All Fields] AND failure[All Fields]) AND tw[All Fields] OR (clinical[All Fields] AND failure[All Fields]) AND tw[All Fields] OR (("virology"[MeSH Terms] OR "virology"[All Fields] OR "virological"[All Fields]) AND failure[All Fields]) AND tw[All Fields]))) AND (((ART(tw) OR antiretroviral therapy(tw) OR ARV(tw) OR antiretroviral(tw) OR HAART(tw))) OR (("art"[MeSH Terms] OR "art"[All Fields]) AND tw[All Fields] OR (("anti-retroviral agents"[All Fields] OR "anti-retroviral agents"[MeSH Terms] OR ("anti-retroviral"[All Fields] AND "agents"[All Fields]) OR "anti-retroviral agents"[All Fields] OR "antiretroviral"[All Fields]) AND ("therapy"[Subheading] OR "therapy"[All Fields] OR "therapeutics"[MeSH Terms] OR "therapeutics"[All Fields])) AND tw[All Fields] OR "arv"[All Fields] AND tw[All Fields] OR ("anti-retroviral agents"[All Fields] OR "anti-retroviral agents"[MeSH Terms] OR ("anti-retroviral"[All Fields] AND "agents"[All Fields]) OR "anti-retroviral agents"[All Fields] OR "antiretroviral"[All Fields]) AND tw[All Fields] OR ("antiretroviral therapy, highly active"[MeSH Terms] OR ("antiretroviral"[All Fields] AND "therapy"[All Fields] AND "highly"[All Fields] AND "active"[All Fields]) OR "highly active antiretroviral therapy"[All Fields] OR "haart"[All Fields]) AND tw[All Fields]))) AND (((Prevalence(tw) OR proportion(tw) OR magnitude(tw) OR risk factors (tw) OR associated factors(tw) OR predictors(tw))) OR (("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "prevalence"[All Fields] OR "prevalence"[MeSH Terms]) AND tw[All Fields] OR proportion[All Fields] AND tw[All Fields] OR magnitude[All Fields] AND tw[All Fields] OR ("risk factors"[MeSH Terms] OR ("risk"[All Fields] AND "factors"[All Fields]) OR "risk factors"[All Fields]) AND tw[All Fields] OR (associated[All Fields] AND factors[All Fields]) AND tw[All Fields] OR predictors[All Fields] AND tw[All Fields]))) AND ((Ethiopia(tw)) OR (("ethiopia"[MeSH Terms] OR "ethiopia"[All Fields]) AND tw[All Fields])). The search was done between March 3 and April 27, 2021. All papers published up to April 27, 2021 were included. Endnote X8 software manager was used to cite references and manage the searched literatures.

Measurement outcome variables

This review has two main outcome variables. The first outcome is HIV/AIDS treatment failure which was defined as immunological, clinical, and virological treatment failure [12]. The second outcome for this study was to identify factors associated with treatment failure. For this outcome, we determined the association between treatment failure and associated factors in the form of the log odds ratio.

Eligibility criteria

Inclusion criteria

Study area: Only studies conducted in Ethiopia were included to produce single estimate of common effects.

Study design: All observational study designs reporting the prevalence of TF were eligible for this meta-analysis.

Population: All HIV-positive children on antiretroviral treatment.

Language: Only articles reported in English language were incorporated.

Publication condition: Both published and unpublished studies were considered.

Exclusion criteria

Conference reports and articles without full text access were excluded. Exclusion of these studies is because of the inability to check the quality of articles in the absence of full text.

Data selection process

The required data from included articles were extracted by two authors (BG and LD) using a standardized data extraction format, adapted from the Joanna Briggs Institute (JBI). Any disagreements during screening were undertaken through discussion. The reviewer contacted the first author(s) of primary research for additional information. The first author name, follow up years, publication year, region, study area, study design, sample size, response rate, and prevalence with 95% CI were included the data selection form.

Quality assessment

The qualities of included articles were evaluated by four investigators (BG, LD, EA and TT) using Newcastle-Ottawa Scale quality assessment tool for observational studies [29]. The tool has three sections; in which the first section focuses on the methodological quality of each primary study (i.e., sample size, response rate, and sampling technique) and graded out of five stars. The second section considers the comparability of the study cases or cohorts with a probability of two stars to be gained. The third section concerns on outcomes and statistical analysis of the primary study with a possibility of three star scores. Any discrepancies between the two quality assessors were resolved by repeating the procedures and involving third reviewer before computing the final appraisal scores. Articles with a score of ≥ 6 for cross-sectional and ≥ 9 for cohort study were considered as high quality respectively.

Data processing and statistical analysis

The required data were extracted using Microsoft Excel and imported into STATA version 14 statistical software for meta-analysis. DerSimonian and Laird’s random-effects model was used to estimate the overall pooled prevalence of treatment failure [30]. The p-values of Cochrane Q-test and I2-statics were computed to assess heterogeneity among reported prevalence [31]. According to the results of statistical test, there was significant heterogeneity among the included original studies (I2 = 94.7%, p<0.001), hereafter, a random-effects meta-analysis model was performed to estimate the pooled prevalence. Subgroup analysis was conducted to adjust random variation between point estimates of original study and investigate how failure fluctuates across subgroup participants. Outlier within the included articles was checked using sensitivity analysis. Publication bias across studies was assessed using funnel plot and egger’s regression test. The Begg’s regression test results at 5% significance level were not statistically significant for publication bias [32]. Forest plot format was used to present the point prevalence and 95% CIs. In this plot, the weight of study indicated by the size of each box, while each crossed line referred to 95% confidence interval. For the secondary outcomes, a log odds ratio was used to determine the association between TF and associated factors.

Results

Study selection

We retrieved 291 relevant articles from PubMed, Google Scholar, Science direct, Scopus, and other sources. Of these initial articles, there were about 236 non-duplicated articles. From the remaining articles, 204 articles were excluded after review of their titles and abstracts. Then, 32 potentially full text articles were assessed for eligibility based on the pre-set criteria and 22 articles were further excluded due to different reasons. Lastly, 10 articles met the eligibility criteria and included in the final meta-analysis to determine the prevalence and associated factors of treatment failure (Fig 1).

Fig 1

PRISMA 2020 flow diagram of primary study selection for systematic review and meta-analysis of treatment failure and associated factors among HIV-positive children in Ethiopia.

Study characteristics

As described in Table 1, the 10 included studies were both cohort and cross-sectional study design, and done from 2003 to 2021. Among the included studies, five studies were conducted in the Amhara region [18,19,24-26], whereas two in Oromia [20,23], two in Addis Ababa [22,27], and one in SNNP [21]. In this meta-analysis study, 4,572 participants were involved to determine the pooled prevalence of treatment failure. The sample size of the studies fluctuated between 96 [20] and 1,186 [22]. Regarding prevalence, the lowest prevalence (3.1%) of treatment failure was reported from a study done in Southern Nations, Nationalities, and Peoples Region (SNNPR) [21], whereas the highest prevalence (18.8%) was reported in study done at Fiche and Kuyu hospitals in Oromia Region [23]. Concerning quality of the included studies, two studies [19,25] were assessed based on JBI check list for cross-sectional studies, and the remaining eight studies [18,20-24,26,27] based on JBI check list for cohort studies. According to this quality assessment criterion, all studies were included.

Table 1

General characteristics of studies included in systematic review and meta-analysis of treatment failure and associated factors among children on ART in Ethiopia 2021.

Author (year)	Study Design	Follow-up (years)	Region	Study area	Sample size	Response rate (%)	Prevalence at 95% CI
Zeleke et al (2016) [18]	Cohort	2005–2013	Amhara	Gondar	225	100	18.2
Bacha et al (2012) [22]	Cohort	2005–2011	Addis Ababa	Addis Ababa	1,186	100	14.1
Sisay et al (2018) [24]	Cohort	2010–2016	Amhara	Amhara	824	81.9	7.7
Yassin et al (2017) [23]	Cohort	2006–2015	Oromia	Fiche and Kuyu	269	86.8	18.8
Netsanet et al (2009)	Cohort	2005–2008	Oromia	Jimma	96	100	11.5
Tadesse et al (2017) [21]	Cohort	2015–2016	SNNP		628	100	3.1
Gelaw et al (2021) [25]	Cross-sectional	2016–2019	Amhara	Bahir Dar	424	94.1	14.8
Yihun et al (2019) [26]	Cohort	2011–2018	Amhara	Debre Markos and Bahir Dar	402	89.8	12.19
Haile et al (2019) [27]	Cohort	2003–2018	Addis Ababa	Addis Ababa	391	81.3	22.6
Getawa et al (2021) [19]	Cross-sectional	2005–2017	Amhara	Gondar	200	100	12.5

Risk of bias in studies

Publication bias was checked using the Begg’s test which showed no statistically significant publication bias with p-value of 0.93. We also performed publication bias assessment for overall treatment failure using funnel plot (Fig 2).

Fig 2

Funnel plot with 95% confidence limits of the pooled prevalence of treatment failure among HIV positive children in Ethiopia.

Results of individual studies

Prevalence of HIV/AIDS treatment failure

The pooled prevalence of treatment failure among HIV-positive children in Ethiopia was found to be 12.34 (95%CI: 8.59, 16.10) (Fig 3).

Fig 3

Forest plot of the pooled prevalence of over-all treatment failure among HIV positive children in Ethiopia.

Based on clinical definition the pooled prevalence of treatment failure was 27.65 (95% CI: 1.23, 54.06) (Fig 4).

Fig 4

Forest plot of the pooled prevalence with corresponding 95% CIs of clinical failure among HIV positive children in Ethiopia.

Concerning immunological failure, the pooled prevalence was 17.97 (95% CI: 10.13, 25.82) (Fig 5).

Fig 5

Forest plot of the pooled prevalence with corresponding 95% CIs of immunological failure among HIV positive children in Ethiopia.

Furthermore, the pooled prevalence of virological treatment failure was 23.93 (95% CI: 3.21, 44.65) (Fig 6).

Fig 6

Forest plot of the pooled prevalence with corresponding 95% CIs of virological failure among HIV positive children in Ethiopia.

Heterogeneity and sensitivity analysis

Heterogeneity test (I2) was 94.7%, p < 0.001 which shows that there is significant variation across the included original studies. In the sensitivity analysis, there is no study away from the lower and upper limit of confidence interval.

Subgroup analysis

To adjust the reported heterogeneity of the study, subgroup analysis was employed based on regions, study design, and sample size. Higher prevalence of treatment failure was observed in Addis Ababa with a prevalence of 15.92 (95% CI: 11.72, 20.12) followed by Oromia regions at 14.47 (95% CI: 9.79, 19.14) (Fig 7).

Fig 7

Forest plot of the prevalence of treatment failure with corresponding 95% CIs of the subgroup analysis based on the regions, where the studies done.

On the other hand, the prevalence of treatment failure was lower in studies having a sample of size 628, 3.03 (95%CI: 1.69, 4.37) compared to those having a sample size 391, 18.41 (95% CI: 14.57, 22.26) (Fig 8).

Fig 8

Forest plot of the prevalence of treatment failure with corresponding 95% CIs of the subgroup analysis based on sample size.

Furthermore, we performed subgroup analysis based on study design. Accordingly, the prevalence of treatment failure in cross-sectional study was 13.43 (95% CI: 10.76, 16.11) and in cohort study 12.14(95% CI: 7.83, 16.44) (Fig 9).

Fig 9

Forest plot of the prevalence of treatment failure with corresponding 95% CIs of the subgroup analysis based on the study design.

Associated factors of HIV/AIDS treatment failure

In this meta-analysis, the associated factors were categorized in to two thematic areas. These were: 1. Socio-demographic 2. Clinical and drug related factors.

Socio-demographic factors

Based on the finding of a study [19], male children were more likely (AOR = 3.15, 95% CI: 1.18, 8.39) to develop HIV treatment failure. From a single study, HIV positive children have not both parents as primary caretakers (AOR = 2.72, 95% CI: 1.05, 7.06], and negative serologic status of their caretakers (AOR = 2.69, 95% CI: 1.03, 7.03) were at high risk of treatment failure [27]. Age of children below 5 years (AOR = 2.4, 95% CI: 1.0–5.7) [25] was also reported as a contributing factor for the occurrence of HIV treatment failure as compared to their counterparts. Likewise, HIV positive children with age below 3 years were at high risk (AHR = 1.85, 95% CI: 1.24, 2.76) to develop treatment failure as compared to those with age between 5 and 15 years [22]. On the other hand, the age of HIV positive children between 6 and 9 years was protective (AOR = 0.26; 95% CI: 0.09, 0.72) from the occurrence of treatment failure compared to age between 10 and 15 years [23].

Clinical and drug related factors

The pooled odds ratio of this meta-analysis revealed that HIV positive children with history of opportunistic infections were 2.6 times more likely (AOR = 2.64; 95% CI: 2.19, 4.31) to develop treatment failure as compared to their counterparts. The estimated pooled effects of advanced WHO clinical stage III/IV on HIV treatment failure was (AOR = 1.66; 95% CI: 1.24, 3.21) as compared to those children categorized on WHO clinical stage I/II. Report from a single study showed that children who interrupt and restart their HIV treatment were positively (AOR = 2.21, 95% CI: 1.09, 4.54) associated with treatment failure [25]. HIV positive children who had height for age below or on 3rd percentile were at high risk (AHR = 3.3, 95% CI: 1.0, 10.6) of treatment failure [22]. Additionally, children who was not disclosed their HIV status were also at high risk (AHR = 4.4, 95% CI: 1.8, 11.3) to develop treatment failure [24]. Original regimen change (AOR = 9.22, 95% CI: 3.36, 25.03) [19] and ART drug substitution (AHR = 1.7, 95% CI: 1.1, 2.7) [22] were reported significantly associated factors HIV treatment failure. The result of this meta-analysis revealed that adherence level was positively associated with HIV treatment failure. From this finding, the estimated pooled effect of poor ART adherence level on childhood HIV treatment failure was (AOR = 2.53; 95% CI: 2.03, 4.97) as compared to good adherence level counterparts.

Discussion

This study was carried out to estimate the nationwide prevalence and associated factors of treatment failure among children in Ethiopia. In this meta-analysis, the overall pooled prevalence of HIV treatment failure was 12.34 (95%CI: 8.59, 16.10). Globally, HIV treatment failure leads the patient to start the more expensive and toxic ART regimen, develop drug resistant viral strains [33]. It is one of the major causes of childhood morbidity and mortality in developing countries including Ethiopia. To the best our knowledge, this meta-analysis is the first of its kind to estimate the pooled prevalence of treatment failure and its associated factors among HIV positive children in Ethiopia. Hence, the result of this review will help the country to keep children on first line treatment regimen.

The finding is in agreement with studies conducted in Malawi (16%) [34] and Ghana (15.7%%) [35]. However, this finding is much lower than studies conducted in Tanzania (25.4%) [36], Uganda and Mozambique (29%) [37], and Kenya (43.1%) [38]. On the other hand, our finding is much higher than a study done in Ghana (6.5%) [39]. The possible explanation for the observed variations might be due to differences in methodology and sample size used to diagnose treatment failure by individual studies conducted in each country. Moreover, the difference could be due to the difference in geographical areas, quality of medical service, and socio-economic status which have an unlimited effect to diagnose HIV treatment failure among children.

There was statistically significant heterogeneity across the original studies included in this review. Therefore, we did subgroup analysis. Accordingly, the subgroup analysis of this study revealed that the highest prevalence of HIV treatment failure was observed in Addis Ababa, 15.92 (95% CI: 11.72, 20.12) followed by Oromia region, 14.47 (95% CI: 9.79, 19.14) whereas the lowest prevalence was identified in SNNPR with a prevalence of 3.03 (95%CI: 1.69, 4.37). The possible explanations for this variation might be due to the difference in sample size, study design, and number of studies included in this review from each region.

In this review, we also investigated factors associated with HIV treatment failure among children taking ART in Ethiopian. Poor ART adherence level, classified as advanced WHO clinical stage III/IV, and history of opportunistic infections were found be the leading factors for the occurrence of childhood treatment failure.

HIV positive children with poor ART adherence level were more likely to experienced treatment failure. After ART is started to HIV infected individuals, it should take for life long without any interruption. If the drug is not taken daily, on time, and regularly; patients are at higher risk drug resistance viral strain. It is widely agreed that good ART adherence has positive impact for suppression of viral replication and improve clinical as well as immunological outcomes which in turn helps to minimize the risk of HIV drug resistance [40]. Approximately 11.3% of HIV positive children have poor ART adhere level which is continued to be a devastating clinical challenge in Ethiopia [41].

Advanced WHO clinical stage is another determinant factor for HIV treatment failure. HIV positive children classified as WHO clinical stage III/IV are more likely to develop treatment failure. Children interrupt to take their medication and lost to follow up which makes them highly vulnerable for opportunistic infections and advanced WHO clinical stage. This makes them to be exposed for HIV treatment failure.

Furthermore, children with lower CD4 cell count and history of opportunistic infections were found to be at high risk to develop HIV treatment failure. This is due to the fact that there is linkage between opportunistic infections and level CD4 cell counts. In human being CD4 cells have its own role on the production of immunity which protects the body from disease causing pathogens. As CD4 cell count decrease, the rate of viral replication on the other hand becomes increased [42,43]. In addition, the care givers as well as patients focus on the current co-infection, missed/interrupt to take their ART drug and follow up which results to develop treatment failure.

Limitations of the review

This review was included only articles studied in the English language, which may limit some papers from being included. Besides, this study represented only studies conducted from three regions and one administrative town of the country, which could under-represent the HIV treatment failure proportion for the entire nationwide context. Moreover, this meta-analysis includes limited number of studies; the result may not represent the nationwide figure of failures.

Conclusion

In this meta-analysis, treatment failure among HIV positive children in Ethiopia was found to be significantly high. Poor ART adherence level, opportunistic infections, and advanced WHO clinical stage were factors significantly associates with treatment failure among HIV positive children in Ethiopia. Thus, based on our results, we recommend particular emphasis shall be given to prevent opportunistic infection and improve treatment adherence level which in turn helps to tackle HIV drug resistance and keep on first line regimen. The result of this review may have implication on clinical and health policy system. Preventing opportunistic infections and improving ART adherence level will be used to increase treatment outcome. Additionally, the finding will help to monitor the national program towards the success of UNAIDS global target of 90-90-90.

PRISMA 2020 checklist.

(DOCX)

Click here for additional data file.

(XLSX)

Click here for additional data file.

18 Nov 2021

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure:

"No funding was obtained for this review"

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Please note that in order to use the direct billing option the corresponding author must be affiliated with the chosen institute. Please either amend your manuscript to change the affiliation or corresponding author, or email us at plosone@plos.org with a request to remove this option.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Authors,

You have presented useful data.

I have the following comments

It will be worthwhile to do a sub-group/sensitivity analysis of cohort and cross-sectional analysis. As, in you may exclude cross-sectional studies and check for the estimates in cohort studies

Repeat it for cross-sectional and compare whether there is a difference

You may also look at Urban/Rural population

Any variables for meta-regression?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

2 Dec 2021

Reviewer #1

Comments to the Author

The authors of this systematic review and meta-analysis have presented useful data to determine the pooled national burden of childhood HIV/AIDS treatment failure as well as its associated factors in Ethiopia. Conversely, there are specific comments that the reviewer would like the authors to address so as to further improvement of the manuscript.

Authors’ response: we are very glad to the reviewer’s appreciation of our efforts; and we have just given our respective responses to each of the specific reviewer comments as detailed below.

1. Is the manuscript technically sound, and do the data support the conclusions?

Thank you very much for your insightful comment. Yes. We have a conclusion which is supported by the data analysed and presented in this study (page 16, line 327-336).

2. Has the statistical analysis been performed appropriately and rigorously?

We acknowledge the reviewer’s concern regarding to statistical analysis for this study. Yes. We have carried out all the necessary statistical analysis properly and presented our finding accordingly in the main documents of this study.

3. Have the authors made all data underlying the findings in their manuscript fully available?

Yes. Comments have been taken and we have made the necessary correction accordingly (page 18, line 357-358). For detail please see the supporting information file.

4. Is the manuscript presented in an intelligible fashion and written in standard English?

Great thanks. We have carefully reviewed the manuscript based on your suggestion and some typographic error has been also updated (page 7, line 153).

5. It will be worthwhile to do a subgroup/sensitivity analysis of cohort and cross-sectional analysis. As, in you may exclude cross-sectional studies and check for the estimates in cohort studies. Repeat it for cross-sectional and compare whether there is a difference. You may also look at Urban/rural population. Any variable for meta-regression?

Absolutely! We have taken the given comment and sensitivity analysis was already done accordingly. However, the result indicated that there is no single study unduly influenced the overall estimates of treatment failure and there is no significant variability for meta-regression. We have done subgroup analysis based on study design, and giving a prevalence of 12.14(95% CI: 7.83, 16.44) in cohort which is nearly the same in cross-sectional study 13.43 (95% CI: 10.76, 16.11) (page 12, line 226-237).

NB. Generally, we have tried to revise our manuscript according to the requirement of PLOS ONE template.

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

7 Dec 2021

Prevalence and associated factors of treatment failure among children on ART in Ethiopia: a systematic review and meta-analysis

PONE-D-21-32599R1

Dear Dr. Gelaw,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

10 Jan 2022

PONE-D-21-32599R1

Prevalence and associated factors of treatment failure among children on ART in Ethiopia: a systematic review and meta-analysis

Dear Dr. Gelaw:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Frank T. Spradley

Academic Editor

PLOS ONE